Lori Greer
Cahaba Cats
http://www.facebook.com/pages/Polyprenyl-Immunostimulant/229781391324
http://www.sassandsass.com/pages/aboutus/news/
The U.S. Department of Agriculture has issued a veterinary biologics
establishment license for the Sass & Sass, Inc. facilities in Oak Ridge, TN
and a conditional license for Polyprenyl Immunostimulant to Sass & Sass,
Inc.
Polyprenyl Immunostimulant is the first treatment intended to aid in the
reduction of clinical signs resulting from a feline rhinotracheitis virus
infection in cats 8 weeks of age or older. Studies of the product efficacy
and safety were performed in collaboration with Dr. Alfred M. Legendre of
the University of Tennessee, Knoxville.
Feline viral rhinotracheitis is an upper respiratory or pulmonary infection
also known as feline influenza. It is caused by feline herpesvirus Type 1.
This disease is highly contagious and has been reported in domestic and wild
cats worldwide. It is ubiquitous in multi-cat environments, including
catteries and shelters. Complications of feline rhinotracheitis are numerous
and may include blindness and death. Feline viral rhinotracheitis is responsible for half of
all respiratory diseases in cats, making it one of the most compelling
feline diseases.
Studies indicate that Polyprenyl Immunostimulant can reduce the severity and
duration of signs of rhinotracheitis, including rhinitis and conjunctivitis.
The product is administered orally, and is recommended for use in cats at
eight weeks of age or older to aid with the control of disease associated
with feline rhinotracheitis virus infection.
USDA granted the conditional license following the acceptance of data
supporting product safety and a reasonable expectation of efficacy. The
safety data included results of studies that evaluated the product both
under normal conditions and in field safety trials in 390 cats in 10 states.
Under the conditional license, the product may be distributed as authorized
in each state, and used by, or under the supervision of, veterinarians.
Sass & Sass, Inc. is a research-driven biotechnology company with a focus on
the development and manufacturing of novel immunomodulatory treatments.
Polyprenyl Immunostimulant is a veterinary biologic which is capable of
regulating immune response in viral diseases and immune disorders, including
herpes and others. Sass & Sass, Inc. holds a US Patent for the composition
and methods, and another patent application is pending. Sass & Sass, Inc.
has developed process and manufactures Polyprenyl Immunostimulant from
domestic raw materials; all phases of manufacturing, packaging and control
are conducted by Sass & Sass, Inc. at its facility in Oak Ridge, TN. The
company has been working with the University of Tennessee Veterinary
Teaching Hospital on clinical trials for feline viral rhinotracheitis,
feline infectious peritonitis, and other diseases.
http://www.sassandsass.com/pages/aboutus/news/
The U.S. Department of Agriculture has issued a veterinary biologics
establishment license for the Sass & Sass, Inc. facilities in Oak Ridge, TN
and a conditional license for Polyprenyl Immunostimulant to Sass & Sass,
Inc.
Polyprenyl Immunostimulant is the first treatment intended to aid in the
reduction of clinical signs resulting from a feline rhinotracheitis virus
infection in cats 8 weeks of age or older. Studies of the product efficacy
and safety were performed in collaboration with Dr. Alfred M. Legendre of
the University of Tennessee, Knoxville.
Feline viral rhinotracheitis is an upper respiratory or pulmonary infection
also known as feline influenza. It is caused by feline herpesvirus Type 1.
This disease is highly contagious and has been reported in domestic and wild
cats worldwide. It is ubiquitous in multi-cat environments, including
catteries and shelters. Complications of feline rhinotracheitis are numerous
and may include blindness and death. Feline viral rhinotracheitis is responsible for half of
all respiratory diseases in cats, making it one of the most compelling
feline diseases.
Studies indicate that Polyprenyl Immunostimulant can reduce the severity and
duration of signs of rhinotracheitis, including rhinitis and conjunctivitis.
The product is administered orally, and is recommended for use in cats at
eight weeks of age or older to aid with the control of disease associated
with feline rhinotracheitis virus infection.
USDA granted the conditional license following the acceptance of data
supporting product safety and a reasonable expectation of efficacy. The
safety data included results of studies that evaluated the product both
under normal conditions and in field safety trials in 390 cats in 10 states.
Under the conditional license, the product may be distributed as authorized
in each state, and used by, or under the supervision of, veterinarians.
Sass & Sass, Inc. is a research-driven biotechnology company with a focus on
the development and manufacturing of novel immunomodulatory treatments.
Polyprenyl Immunostimulant is a veterinary biologic which is capable of
regulating immune response in viral diseases and immune disorders, including
herpes and others. Sass & Sass, Inc. holds a US Patent for the composition
and methods, and another patent application is pending. Sass & Sass, Inc.
has developed process and manufactures Polyprenyl Immunostimulant from
domestic raw materials; all phases of manufacturing, packaging and control
are conducted by Sass & Sass, Inc. at its facility in Oak Ridge, TN. The
company has been working with the University of Tennessee Veterinary
Teaching Hospital on clinical trials for feline viral rhinotracheitis,
feline infectious peritonitis, and other diseases.